Gilles A. Salles
吉勒斯·萨莱斯
MD, PhD
Chief, Lymphoma Service; Attending Physician; Professor of Medicine, Weill Cornell Medical College淋巴瘤科主任；主治医师；威尔康奈尔医学院医学教授
👥Biography 个人简介
Gilles A. Salles, MD, PhD is Chief of the Lymphoma Service and Attending Physician at Memorial Sloan Kettering Cancer Center, and Professor of Medicine at Weill Cornell Medical College. Before joining MSK, he led the hematology program at the University of Lyon (Hospices Civils de Lyon) in France, where he built one of Europe's most productive lymphoma research groups. Dr. Salles is internationally recognized as a global leader in follicular lymphoma biology, treatment optimization, and novel immunotherapy development — most notably as a principal investigator in the development of mosunetuzumab, the first CD20×CD3 bispecific T-cell engager antibody to receive regulatory approval for follicular lymphoma. His pivotal phase II study (published in Nature Medicine 2022) demonstrated that mosunetuzumab achieves high rates of complete response (60%) and durable remissions in multiply relapsed/refractory follicular lymphoma, providing an off-the-shelf, fixed-duration outpatient immunotherapy option that led to accelerated FDA approval and EMA conditional approval of mosunetuzumab for this indication. Dr. Salles has also led or co-led the PRIMA trial (establishing rituximab maintenance in first-line follicular lymphoma), RELEVANCE (lenalidomide-rituximab in frontline FL), and multiple other follicular lymphoma trials. He has been president of the International Conference on Malignant Lymphoma (ICML) and has chaired EHA and ESMO scientific programs for lymphoma.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Mosunetuzumab — First Approved CD20×CD3 Bispecific T-Cell Engager in Follicular Lymphoma
Led the pivotal phase II single-agent mosunetuzumab study (Nature Medicine 2022) in relapsed/refractory follicular lymphoma demonstrating an ORR of 80% and complete response rate of 60% in patients with a median of 3 prior lines of therapy, including anti-CD20- and PI3K inhibitor-refractory cases, with fixed-duration (8 cycles) outpatient administration and durable responses — data that supported accelerated FDA approval (December 2022) and EMA conditional approval of mosunetuzumab, establishing bispecific T-cell engagers as a transformative treatment class in indolent B-NHL.
PRIMA Trial — Rituximab Maintenance in First-Line Follicular Lymphoma
Led the international phase III PRIMA trial (Lancet 2011) demonstrating that 2-year rituximab maintenance following first-line R-chemotherapy significantly improved progression-free survival (HR 0.55) compared with observation in follicular lymphoma patients achieving at least a partial response, establishing rituximab maintenance as an international standard of care that markedly improved 3-year PFS rates and transformed the frontline FL management paradigm.
RELEVANCE Trial — R2 vs. R-Chemotherapy in Front-Line Follicular Lymphoma
Led the international phase III RELEVANCE trial comparing lenalidomide-rituximab (R2) with rituximab-chemotherapy in previously untreated follicular lymphoma, demonstrating that R2 achieved similar progression-free and overall survival outcomes as chemoimmunotherapy with a distinct and manageable toxicity profile, establishing the scientific rationale for chemotherapy-free first-line approaches and informing ongoing frontline FL trial design.
Bispecific Antibody Clinical Development Framework in B-NHL
Has been a leading global architect of the bispecific antibody clinical development landscape in B-NHL, contributing as principal or co-investigator to trials of multiple CD20×CD3 bispecific molecules (glofitamab, epcoritamab, odronextamab) and pioneering the integration of step-up dosing schedules to mitigate cytokine release syndrome — innovations that have enabled outpatient administration of T-cell engaging antibodies and have become standard practice across bispecific antibody trials in lymphoma.
Representative Works 代表性著作
Mosunetuzumab in relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study
Nature Medicine (2022)
Pivotal phase II study establishing mosunetuzumab as the first approved CD20×CD3 bispecific T-cell engager in follicular lymphoma with high CR rate and durable remissions.
Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA)
The Lancet (2011)
Phase III PRIMA trial establishing 2-year rituximab maintenance as standard of care after first-line R-chemotherapy in high-tumor-burden follicular lymphoma.
Lenalidomide plus rituximab versus chemotherapy plus rituximab for first-line treatment of follicular lymphoma (RELEVANCE)
New England Journal of Medicine (2018)
Phase III RELEVANCE trial showing R2 achieves equivalent outcomes to R-chemotherapy in front-line follicular lymphoma with distinct toxicity profile, supporting chemotherapy-free approaches.
Prognostic significance of CD20 expression in follicular lymphoma
Blood (2007)
Analysis of CD20 expression patterns and their relationship to rituximab response and clinical outcomes in follicular lymphoma, informing anti-CD20 therapy optimization.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-04-06 | All information from publicly available academic sources
Related Experts 相关专家
Hope S. Rugo
University of California, San Francisco (UCSF)
Maryam B. Lustberg
Yale School of Medicine / Yale Cancer Center
Sara M. Tolaney
Dana-Farber Cancer Institute / Harvard Medical School
Carlos H. Barrios
PUCRS (Pontifical Catholic University of Rio Grande do Sul) / Hospital São Lucas, Porto Alegre, Brazil
关注 吉勒斯·萨莱斯 的研究动态
Follow Gilles A. Salles's research updates
留下邮箱，当我们发布与 Gilles A. Salles（Memorial Sloan Kettering Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment